Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2016 01:15 ET | Source: Novartis Pharma AG

Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain

Cosentyx® data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years[1]* New data show that with Cosentyx the high ACR...
November 13, 2016 19:01 ET | Source: Novartis Pharma AG

Novartis improves ranking in 2016 Access to Medicine Index

Novartis ranks third in 2016 ranking Company tops the industry in access-to-medicine management and capacity building Novartis integrated access strategy addressing all income segments...
November 01, 2016 02:15 ET | Source: Novartis Pharma AG

Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer

Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared...
October 31, 2016 02:15 ET | Source: Novartis Pharma AG

Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product

Basel, October 31, 2016 - Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation...
October 25, 2016 01:00 ET | Source: Novartis Pharma AG

Novartis a réalisé un troisième trimestre solide, les produits de croissance[1] ayant compensé l'expiration du brevet de Glivec; plusieurs résultats positifs concernant des blockbusters potentiels

Chiffre d'affaires net du T3 (-1% tcc[2] et USD) largement comparable au T3 2015 grâce à l'excellente performance des produits de croissance Gilenya (USD 790 millions, +15% tcc) a poursuivi sa...
October 25, 2016 01:00 ET | Source: Novartis Pharma AG

Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters

Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301...
October 25, 2016 01:00 ET | Source: Novartis Pharma AG

Novartis erzielt im dritten Quartal solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust des Patents für Gleevec wettmachen; mehrere positive Daten für potenzielle Blockbuster

Dank starker Performance der Wachstumsprodukte bleibt der Nettoumsatz im dritten Quartal (-1% kWk[2] und USD) weitgehend unverändert gegenüber dem Vorjahreszeitraum Gilenya (USD 790 Millionen,...
October 17, 2016 17:00 ET | Source: Novartis Pharma AG

Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting

Alcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle...
October 09, 2016 02:15 ET | Source: Novartis Pharma AG

Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study

Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in...
October 08, 2016 02:30 ET | Source: Novartis Pharma AG

Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up

Latest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year...